reduc rate buy neutral fairli valu
upgrad march per share compani
deliv strong earn multipl catalyst like sale imag busi
acquisit euroimmun also transform growth mid-singl
digit better guidanc lower growth fewer catalyst ahead
see equiti fairli valu reduc rate buy neutral
earn report post strong organ growth rate
higher expect noisi top bottom line
due fx headwind unplan incent compens expens non-
gaap ep versu guidanc ex certain item non-gaap
ep would fx impact earn unplan
lt compens expens impact earn revenu slightli
light compar street compani lower
revenu guidanc lower earn guidanc nickel
updat model reflect downward revis guidanc
first time call capabl burgeon cannabi qa/
qc market base small around mn howev expect doubl
next year potenti mn market opportun futur
see stock fairli valu fv reach appli
multipl consolid ep fv also
reach appli da revenu estim
per share dx revenu per
share less net debt per share
million except per share data
euroimmun inc dx
co guidanc includ mn euroimmun
annual revenu break-out margin
revenu
total sale
revenu
